Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Diabetes, GPCRs, and islet macrophages
  • DREADDs as pathway-first tools for antidiabetic target discovery
  • Role of myeloid Gq activation
  • Lipid metabolism remodeling relays macrophage signals to β cells
  • GPR18 provides an endogenous entry point
  • From mechanistic insight to therapeutic opportunities
  • Manuscript information
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Commentary Open Access | 10.1172/JCI212477

Chemogenetics reveals a surprising role for GPR18 signaling in immunometabolic regulation of β cell activity

Xianglin Huang and Bryan L. Roth

Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Address for correspondence. Bryan L. Roth, Room 2113, Genetic Medicine Building, 120 Mason Farm Road, Chapel Hill, North Carolina 27599, USA. Email: bryan_roth@med.unc.edu.

Find articles by Huang, X. in: PubMed | Google Scholar

Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Address for correspondence. Bryan L. Roth, Room 2113, Genetic Medicine Building, 120 Mason Farm Road, Chapel Hill, North Carolina 27599, USA. Email: bryan_roth@med.unc.edu.

Find articles by Roth, B. in: PubMed | Google Scholar

Published November 16, 2026 - More info

Published in Volume 136, Issue 22 on November 16, 2026
J Clin Invest. 2026;136(22):e212477. https://doi.org/10.1172/JCI212477.
© 2026 Huang et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 16, 2026 - Version history
View PDF

Related article:

Acute activation of Gq signaling in pancreatic islet macrophages inhibits insulin secretion through AMPK/sphingolipid axis
Simran Singh, Ashish Kumar, Sudipta Paul, Mriganka Sarkar, Santhosh Duraisamy, Ganesh Timalsina, Raashidha Farhath, Harender Yadav, Seema Kuldeep, Soumita Bhaumik, Kunj Kumar Prajapati, Saahiba Thaleshwari, Anuj Gargya, Tamojit Santra, Sonal Amit, Rashmi Parihar, Santosh K. Misra, Hamim Zafar, Luiz F. Barella, Michael A. Kalwat, Dharmaraja Allimuthu, Sai Prasad Pydi
Simran Singh, Ashish Kumar, Sudipta Paul, Mriganka Sarkar, Santhosh Duraisamy, Ganesh Timalsina, Raashidha Farhath, Harender Yadav, Seema Kuldeep, Soumita Bhaumik, Kunj Kumar Prajapati, Saahiba Thaleshwari, Anuj Gargya, Tamojit Santra, Sonal Amit, Rashmi Parihar, Santosh K. Misra, Hamim Zafar, Luiz F. Barella, Michael A. Kalwat, Dharmaraja Allimuthu, Sai Prasad Pydi
We show islet macrophages acutely suppress insulin secretion via a GPR18–Gq–AMPK–sphingolipid axis—revealing lipid-based immune–β-cell crosstalk as a target in obesity and diabetes.
Research Article Endocrinology Metabolism

Acute activation of Gq signaling in pancreatic islet macrophages inhibits insulin secretion through AMPK/sphingolipid axis

  • Text
  • PDF
Abstract

Obesity-associated inflammation impairs pancreatic β cell function, yet the mechanisms by which immune cells acutely regulate insulin secretion remain poorly defined. Here, we identify myeloid Gq signaling as an immunometabolic node linking macrophage lipid sensing to impaired insulin secretion. Using chemogenetic DREADD-mediated activation of myeloid Gq, we show that acute macrophage Gq activation impairs glucose-stimulated insulin secretion (GSIS) in vivo, whereas myeloid Gαq ablation enhances GSIS. Mechanistically, Gq activation rapidly induced AMPK phosphorylation and sphingolipid remodeling independently of canonical inflammatory cytokines. Macrophage-derived sphingolipids impaired β cell insulin signaling and GSIS through CD36/PKCζ, while inhibition of CD36, AMPK, or sphingolipid metabolism restored β cell function. We further identified GPR18, a Gq-coupled endocannabinoid-responsive GPCR, as an upstream regulator. GPR18 activation with N-arachidonoyl glycine (NAGly) recapitulated this phenotype, whereas myeloid Gαq deletion or Gpr18/AMPK silencing abolished it. GPR18 signaling predominantly engaged Gq rather than Gi pathways. In human tissues, GPR18 was enriched in islet macrophages, and NAGly suppressed GSIS in primary human islets. Thus, a conserved macrophage GPR18/Gαq/AMPK/sphingolipid axis dynamically regulates β cell function and represents a potential therapeutic target in obesity and type 2 diabetes.

Authors

Simran Singh, Ashish Kumar, Sudipta Paul, Mriganka Sarkar, Santhosh Duraisamy, Ganesh Timalsina, Raashidha Farhath, Harender Yadav, Seema Kuldeep, Soumita Bhaumik, Kunj Kumar Prajapati, Saahiba Thaleshwari, Anuj Gargya, Tamojit Santra, Sonal Amit, Rashmi Parihar, Santosh K. Misra, Hamim Zafar, Luiz F. Barella, Michael A. Kalwat, Dharmaraja Allimuthu, Sai Prasad Pydi

×

Abstract

Pancreatic islet macrophages are important immunometabolic regulators of β cell function, particularly in obesity-associated type 2 diabetes. Previous studies have established that pancreatic islet macrophages communicate with β cells through either the release of cytokines and growth factors, or direct cell–cell contact. In this issue of the JCI, Singh et al. used chemogenetics to identify a Gq/AMPK pathway that remodels sphingolipid metabolism. This pathway links macrophages to β cells through a CD36-dependent mechanism that reduces insulin secretion. Surprisingly, the orphan GPCR GPR18 was identified as the receptor that engages this pathway. These findings expand our understanding in macrophage–β cell communication and identify GPR18 as a potential therapeutic target for type 2 diabetes.

Diabetes, GPCRs, and islet macrophages

Type 2 diabetes (T2D) is one of the most prevalent and rapidly growing chronic metabolic disorders worldwide, affecting approximately one in nine adults aged 20–79 in 2024 (1, 2). This complex disease emerges from interactions between insulin resistance, progressive β cell dysfunction, altered nutrient handling, and chronic inflammation across multiple tissues. The clinical success of glucagon-like peptide-1 receptor (GLP-1R) agonists and dual- or triple-action agonists targeting the GLP-1R/gastric inhibitory polypeptide receptor/glucagon receptor illustrates the therapeutic power of accurately targeting GPCRs in metabolic disease, especially in T2D.

Pancreatic islet macrophages have attracted increasing attention as immunometabolic regulators of β cell adaptation and failure. In obesity, these macrophages can adopt inflammatory states and release proinflammatory cytokines such as IL-1β, leading tο pancreatic β cell dysfunction and apoptosis (3, 4). Moreover, resident intra-islet macrophages can engulf insulin secretory granules from β cells through direct cell–cell interactions, but they can also compensate for this effect on β cell output by promoting β cell proliferation through platelet-derived growth factor receptor signaling (5). Many GPCRs in macrophages have also been found to mediate important communication between islet macrophages and β cells in response to metabolic stress due to obesity (Figure 1). Activation of free fatty acid receptor 4 (also known as GPR120) by fatty acids leads to IL-6 secretion and promotes insulin secretion from β cells, an effect that is impaired in obesity-associated diabetes (6). Lysophosphatidic acid receptor 5 (GPR92) similarly promotes antiinflammatory responses to improve β cell insulin secretion (7). Conversely, GPR132 shows an increased expression level in islet macrophages under high-fat diet (HFD) conditions and promotes macrophage reprogramming that impairs glucose sensing and insulin secretion. Both functions of GPR132 could be restored by a selective antagonist (8). Together, these findings position islet macrophage GPCR signaling as a potentially druggable interface between metabolic stress and β cell function.

The orphan GPCR GPR18 engages a pancreatic macrophage–β cell signaling pathFigure 1

The orphan GPCR GPR18 engages a pancreatic macrophage–β cell signaling pathway that reduces insulin secretion. (A) Using Gq-coupled DREADD, Singh et al. (15) identified a Gq/AMPK/sphingolipid signaling pathway in macrophage–β cell communications. Selective activation of Gq-DREADD led to increased activation of AMPK, which remodeled the sphingolipid recycling pathways and led to release of sphingolipids and their derivatives from macrophages. CD36 on β cells facilitated the uptake of these lipids into β cells, leading to increased phosphorylation of PKCζ as well as reduced phosphorylation of AKT and GSK3β. The activation of GSK3β resulted in reduced insulin secretion. Singh et al. then identified GPR18 as an endogenous GPCR mediating this Gq-dependent pathway. (B) These findings position GPR18 as a potential target in T2D, alongside other GPCRs that have been implicated in insulin-regulating macrophage–β cell interactions.

DREADDs as pathway-first tools for antidiabetic target discovery

Designer receptors exclusively activated by designer drugs (DREADDs) provide a way to interrogate GPCR biology with spatial and temporal control. DREADDs are engineered GPCRs that selectively activate one of several signal transduction pathways (Gq/11, Gs, Gi, G12/13, or β-arrestin) in response to a specific synthetic compound rather than endogenous ligands. Since the development of the conventional DREADD platform as a practical in vivo tool (9, 10), it has been broadly used to establish the relationships between cell-specific GPCR signaling and (patho)physiological responses and to discover and prevalidate therapeutically relevant pathways. This pathway-first strategy has been particularly informative in the research of metabolic diseases, especially in T2D, which results from imbalances across multiple cell types, including but not limited to the pancreatic cells, hepatocytes, and adipocytes (8). Early studies expressing Gq- or Gs-coupled designer receptors selectively in pancreatic β cells of transgenic mice showed that activating either pathway increased insulin release (11). Identifying pathologically relevant pathways can then direct the discovery and validation of endogenous therapeutic targets.

DREADDs were later employed to probe the effects of acute Gq activation (12) and Gi activation (13) in hepatocytes, identifying that both lead to increased hepatic glucose production and impaired glucose homeostasis. These studies resulted in the identification of V1b-vasopressin and CB1-cannabinoid receptors as potential targets in T2D. Similarly, selective Gq activation in adipocytes was found to improve glucose homeostasis and tolerance, revealing the beneficial effects of activating cysteinyl leukotriene receptor 2 (14). Given the crucial role of macrophages in obesity-associated islet remodeling, extending this approach to investigate the pathway-specific effects in these cells offers opportunities to discover unexplored GPCR targets.

Role of myeloid Gq activation

In this issue of the JCI, Singh and colleagues applied this DREADD-based strategy to identify pathways involved in macrophage regulation of β cell function (15). Singh et al. first identified Gq signaling as a candidate pathway by analyzing public scRNA-seq data from cells in pancreatic islets of mice fed regular chow (RC; non-diabetic control) or an HFD (diet-induced obesity diabetic model). They found that the Gnaq expression level in M1 macrophages was significantly higher under the HFD than the RC condition. Similar changes in BMDMs, together with the positive correlation between Gnaq expression level in human PBMCs and body mass index, motivated a direct test of the functional consequences of Gq activation.

To selectively probe the role of Gq activation in macrophages, Singh et al. created a GqD mouse line with myeloid-specific expression of the Gq-coupled DREADD receptor hM3Dq (9). Administration of the selective chemogenetic ligand deschloroclozapine (DCZ) activated GqD in myeloid cells, including but not limited to macrophages, and produced changes in both glucose homeostasis and β cell insulin secretion. DCZ increased blood glucose and reduced plasma insulin levels in both RC- and HFD-fed mice, with no changes in insulin sensitivity or oral glucose tolerance. Among four insulinotropic stimuli tested, GqD stimulation impaired glucose-stimulated insulin secretion and arginine-stimulated insulin secretion in both RC- and HFD-fed mice and impaired insulin response to glyburide and GLP-1R agonist exendin-4 in HFD-fed mice. Reduced insulin secretion in response to all four insulinotropic stimuli was also observed in isolated islets from the LysM-GqDREADD mice in the presence of DCZ and was rescued with treatment of clodronate liposomes, which selectively deplete islet macrophages.

Importantly, the converse genetic experiment supported the same conclusion regarding the role of Gq. Here, myeloid-specific Gq deletion enhanced glucose-stimulated insulin secretion and therefore improved glucose clearance. Together, these complementary gain- and loss-of-function experiments elucidate the role of myeloid Gq activation in restraining insulin secretion in β cells.

Lipid metabolism remodeling relays macrophage signals to β cells

Next, the authors showed that although in vivo activation of GqD did not alter circulating or transcript levels of typical pro- or antiinflammatory cytokines, it was associated with changes in sphingolipid metabolism (15). Lipidomic profiling revealed that ceramide and sphingomyelin species increased in both cell lysates and conditioned medium from BMDMs as well as in the whole pancreatic islet following DCZ administration, suggesting that islet macrophages actively metabolized and secreted sphingolipids, which could then affect the neighboring β cells. The Gq-triggered regulation of lipid metabolism occurred through the activation of AMPK, and the Gq-AMPK activation did not affect de novo sphingolipid synthesis but instead regulated the recycling of preexisting sphingolipids to ceramide, remodeling the local composition of sphingolipid intermediates.

The local sphingolipid intermediates then relayed the signals through a mechanism involving the lipid transport protein CD36, PKCζ, AKT, and glycogen synthase kinase 3 beta (GSK3β) (Figure 1). Ultimately, reduced GSK3β Ser9 phosphorylation disinhibited its kinase activity in β cells, leading to effects such as the destabilization of core transcription factors and therefore reduced secretory competence. Pretreatment with the CD36 inhibitor sulfosuccinimidyl oleate restored the insulin secretion from INS-1 β cells exposed to conditioned media from GqD-activated macrophages, supporting the CD36-dependent model. The conceptual advance is that macrophages can also influence β cells through changes in the local lipid environment, in addition to cytokine release or direct contact.

GPR18 provides an endogenous entry point

Having identified the Gq/AMPK/sphingolipid/CD36/PKCζ/AKT/GSK3β axis connecting macrophages and β cells, Singh et al. next searched for an endogenous macrophage GPCR capable of engaging it (15). Murine macrophage scRNA-seq data and qPCR validation in BMDMs and isolated islets identified GPR18 as a candidate upstream regulator. GPR18 expression level also correlated positively with body weight and blood glucose level. Stimulation with the GPR18 agonist N-arachidonoyl glycine successfully reproduced the key effects of chemogenetic Gq activation: reduced insulin secretion in response to glucose, arginine, and glyburide; accumulation of sphingolipid species; increased AMPK phosphorylation; and reduced AKT phosphorylation. Perturbing the axis using knockdown of GPR18 or AMPK using siRNA, myeloid Gq knockout, or treatment with clodronate liposomes prevented GPR18-induced impairment of insulin secretion from β cells, demonstrating the validity and importance of the GPR18/Gq/AMPK/sphingolipid axis in islet macrophage–β cell signaling (Figure 1). This pathway was also found to be conserved in human immune cells and islets. Importantly, these findings show how chemogenetics can be employed to identify candidate druggable targets — in this case, GPR18.

From mechanistic insight to therapeutic opportunities

Several questions remain to be resolved before the pathway Singh et al. described can be translated into therapeutic benefits. How is GPR18 engaged during disease progression: does it occur via altered ligand availability or increased receptor expression? How do individual sphingolipid species contribute to β cell dysfunction? Emerging work by the same research group has suggested that distinct macrophage pathways provide additional regulation of insulin secretion and sensitivity, thereby revealing a largely unexplored GPCR signaling map in islet macrophages (16). Together, the identification of the GPR18/Gq/AMPK/sphingolipid pathway expands our understanding of how islet macrophages affect endocrine function and provides exciting opportunities to selectively interrupt pathologic macrophage–β cell communication without perturbing beneficial macrophage functions.

Manuscript information

AI disclosure. The authors used ChatGPT-5.6 Sol (OpenAI) to improve the readability and clarity of the text (September 12, 2026).

Conflict of interest. BLR is a member of the scientific advisory board of Epiodyne, XyloBio, SkapeBio, and ImprintBio. The University of North Carolina has licensed technologies from the Roth lab to many biotechnology and pharmaceutical companies.

Footnotes

Copyright: © 2026, Huang et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2026;136(22):e212477. https://doi.org/10.1172/JCI212477.

See the related article at Acute activation of Gq signaling in pancreatic islet macrophages inhibits insulin secretion through AMPK/sphingolipid axis.

Address for correspondence. Bryan L. Roth, Room 2113, Genetic Medicine Building, 120 Mason Farm Road, Chapel Hill, North Carolina 27599, USA. Email: bryan_roth@med.unc.edu.

References
  1. Magliano DJ, Boyko EJ. The global picture of diabetes. In: Diabetes Atlas [Internet]. 11th Edition. International Diabetes Federation; 2025. https://www.ncbi.nlm.nih.gov/books/NBK618744/ Accessed September 13, 2026.
  2. Davies MJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2026;12(1):13.
    View this article via: CrossRef PubMed Google Scholar
  3. Jourdan T, et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med. 2013;19(9):1132–1140.
    View this article via: CrossRef PubMed Google Scholar
  4. Fang S, et al. NOX2-dependent macrophage-β-cell crosstalk exacerbate islet dysfunction in type 2 diabetes. Biochim Biophys Acta Mol Basis Dis. 2026;1872(8):168392.
    View this article via: CrossRef PubMed Google Scholar
  5. Ying W, et al. Expansion of islet-resident macrophages leads to inflammation affecting β cell proliferation and function in obesity. Cell Metab. 2019;29(2):457–474.
    View this article via: CrossRef PubMed Google Scholar
  6. Chen X, et al. FFAR4-mediated IL-6 release from islet macrophages promotes insulin secretion and is compromised in type-2 diabetes. Nat Commun. 2025;16(1):3422.
    View this article via: CrossRef PubMed Google Scholar
  7. de Souza CO, et al. GPR92 activation in islet macrophages controls β cell function in a diet-induced obesity model. J Clin Invest. 2022;132(21):e160097.
    View this article via: JCI CrossRef PubMed Google Scholar
  8. Wang JL, et al. Functional screening and rational design of compounds targeting GPR132 to treat diabetes. Nat Metab. 2023;5(10):1726–1746.
    View this article via: CrossRef PubMed Google Scholar
  9. Armbruster BN, et al. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A. 2007;104(12):5163–5168.
    View this article via: CrossRef PubMed Google Scholar
  10. Alexander GM, et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron. 2009;63(1):27–39.
    View this article via: CrossRef PubMed Google Scholar
  11. Guettier JM, et al. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A. 2009;106(45):19197–19202.
    View this article via: CrossRef PubMed Google Scholar
  12. Hua Li J, et al. A novel experimental strategy to assess the metabolic effects of selective activation of a G(q)-coupled receptor in hepatocytes in vivo. Endocrinology. 2013;154(10):3539–3551.
    View this article via: CrossRef PubMed Google Scholar
  13. Rossi M, et al. Hepatic Gi signaling regulates whole-body glucose homeostasis. J Clin Invest. 2018;128(2):746–759.
    View this article via: JCI CrossRef PubMed Google Scholar
  14. Kimura T, et al. Adipocyte Gq signaling is a regulator of glucose and lipid homeostasis in mice. Nat Commun. 2022;13(1):1652.
    View this article via: CrossRef PubMed Google Scholar
  15. Singh S, et al. Acute activation of Gq signaling in pancreatic islet macrophages inhibits insulin secretion through AMPK/sphingolipid axis. J Clin Invest. 2026;136(22):e202344.
    View this article via: JCI PubMed CrossRef Google Scholar
  16. Kuldeep S, et al. Myeloid Gi signaling acts as a weight-independent immunometabolic switch controlling systemic insulin sensitivity [preprint]. https://doi.org/10.64898/2026.03.28.713834 Posted on bioRxiv March 31, 2026.
Version history
  • Version 1 (November 16, 2026): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Diabetes, GPCRs, and islet macrophages
  • DREADDs as pathway-first tools for antidiabetic target discovery
  • Role of myeloid Gq activation
  • Lipid metabolism remodeling relays macrophage signals to β cells
  • GPR18 provides an endogenous entry point
  • From mechanistic insight to therapeutic opportunities
  • Manuscript information
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts